



Johnson & Johnson Reports 2009 Second-Quarter Results:

--Sales of \$15.2 Billion Decreased 7.4% Versus 2008 Second Quarter --EPS of \$1.15 Decreased 2.5%* Versus 2008 Second Quarter, Excluding 2008 Special Items

NEW BRUNSWICK, N.J., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of \$15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%. Domestic sales declined 6.7%, while international sales declined 8.0%, reflecting operational growth of 3.9% and a negative currency impact of 11.9%.

Net earnings and diluted earnings per share for the second quarter of 2009 were \$3.2 billion and \$1.15, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of \$40 million. Excluding this charge, net earnings for the quarter and diluted earnings per share represent decreases of 4.7% and 2.5%, respectively, as compared to the same period in 2008.* The Company confirmed its earnings guidance for full-year 2009 of \$4.45 - \$4.55 per share, which excludes the impact of special items.

"I am proud of the accomplishments of our people in continuing to deliver very solid operational results in light of the significant impacts of patent expirations and the economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "Our investments through internal research and development, strategic partnerships and acquisitions have allowed us to build what is considered by many to be one of the best pipelines in our industry. We will continue to invest in our portfolio of innovative products to meet the needs of patients and consumers around the world."

Worldwide Consumer sales of \$3.9 billion for the second quarter represented a decrease of 4.5% versus the prior year with an increase of 3.1% operationally and a negative impact from currency of 7.6%. Domestic sales increased 0.8%; while international sales decreased 8.4%, which reflected an operational increase of 4.7% and a negative currency impact of 13.1%.

LISTERINE® antiseptic mouthrinse and the skin care lines of NEUTROGENA® and AVEENO® contributed to operational sales growth during the quarter. Other growth drivers were sales from the recently completed acquisition of the French company Vania Expansion SNC.

Worldwide Pharmaceutical sales of \$5.5 billion for the second quarter represented a decrease versus the prior year of 13.3% with an operational decline of 8.5% and a negative impact from currency of 4.8%. Domestic sales decreased 16.4%; while international sales decreased 8.7%, which reflected an operational increase of 3.3% and a negative currency impact of 12.0%.

REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and CONCERTA® (methylphenidate HCl), a treatment for attention deficit hyperactivity disorder, had strong operational sales performance during the quarter. Sales results of TOPAMAX® (topiramate), an anti-epileptic, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI™ (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, active psoriatic arthritis with or without methotrexate, and active ankylosing spondylitis. The FDA also approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder. The Drug Enforcement Administration (DEA) issued their final ruling and placed NUCYNTA™ (tapentadol) CII immediate release tablets for the relief of moderate to severe acute pain in patients 18 years of age or older into Schedule II of the Controlled Substances Act. The product is now available to patients.

The Company also announced a definitive agreement to acquire Cougar Biotechnology, a development stage biopharmaceutical company with a specific focus on oncology, for approximately \$1.0 billion in a cash tender offer. On July 9, 2009, the acquisition of Cougar Biotechnology was completed. On July 2, 2009, the Company announced a definitive agreement with Elan Corporation, plc. whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program and will invest \$1 billion in Elan newly issued American Depositary Receipts (ADRs).

Worldwide Medical Devices and Diagnostics sales of \$5.9 billion for the second quarter represented a decrease of 3.1% versus the prior year with an operational increase of 2.9% and a negative currency impact of 6.0%. Domestic sales increased 1.9%;

while international sales decreased 7.2%, which reflected an operational increase of 3.7% and a negative currency impact of 10.9%.

Primary contributors to the operational growth included Ethicon's surgical care products; Ortho-Clinical Diagnostics' professional products; Ethicon Endo-Surgery's minimally invasive products; and DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses. Also contributing to growth were sales of products acquired as part of the completed acquisition of Mentor Corporation, a leading supplier of medical products for the global aesthetic market. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market as well as the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time. . .inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

Percent Change

	2009	2008	Total	Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,708	1,694	0.8%	0.8	-
International	2,146	2,342	(8.4)	4.7	(13.1)
	3,854	4,036	(4.5)	3.1	(7.6)

	-----	-----	----	---	----
Pharmaceutical					
U.S.	3,172	3,793	(16.4)	(16.4)	-
International	2,326	2,547	(8.7)	3.3	(12.0)
-----	-----	-----	----	---	----
	5,498	6,340	(13.3)	(8.5)	(4.8)
	-----	-----	----	---	----
Med Devices & Diagnostics					
U.S.	2,776	2,723	1.9	1.9	-
International	3,111	3,351	(7.2)	3.7	(10.9)
-----	-----	-----	----	---	----
	5,887	6,074	(3.1)	2.9	(6.0)
	-----	-----	----	---	----
U.S.	7,656	8,210	(6.7)	(6.7)	-
International	7,583	8,240	(8.0)	3.9	(11.9)
-----	-----	-----	----	---	----
Worldwide	\$15,239	16,450	(7.4)%	(1.4)	(6.0)
-----	-----	-----	----	---	----

(Unaudited; Dollars in Millions)

SIX MONTHS

			Percent Change		
	2009	2008	Total Operations	Currency	
-----	-----	-----	-----	-----	-----
Sales to customers by segment of business					
Consumer					
U.S.	\$3,434	3,513	(2.2)%	(2.2)	-
International	4,131	4,587	(9.9)	3.6	(13.5)
-----	-----	-----	----	---	----
	7,565	8,100	(6.6)	1.0	(7.6)
	-----	-----	----	---	----
Pharmaceutical					
U.S.	6,846	7,863	(12.9)	(12.9)	-
International	4,432	4,906	(9.7)	3.1	(12.8)
-----	-----	-----	----	---	----
	11,278	12,769	(11.7)	(6.8)	(4.9)
	-----	-----	----	---	----
Med Devices & Diagnostics					
U.S.	5,428	5,311	2.2	2.2	-
International	5,994	6,464	(7.3)	3.6	(10.9)
-----	-----	-----	----	---	----
	11,422	11,775	(3.0)	3.0	(6.0)
	-----	-----	----	---	----
U.S.	15,708	16,687	(5.9)	(5.9)	-
International	14,557	15,957	(8.8)	3.5	(12.3)
-----	-----	-----	----	---	----
Worldwide	\$30,265	32,644	(7.3)%	(1.3)	(6.0)
-----	-----	-----	----	---	----

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER				
			Percent Change		
	2009	2008	Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$7,656	8,210	(6.7)%	(6.7)	-
Europe	3,972	4,547	(12.6)	1.8	(14.4)
Western Hemisphere excluding U.S.	1,215	1,280	(5.1)	11.7	(16.8)
Asia-Pacific, Africa	2,396	2,413	(0.7)	3.7	(4.4)
International	7,583	8,240	(8.0)	3.9	(11.9)
Worldwide	\$15,239	16,450	(7.4)%	(1.4)	(6.0)

(Unaudited; Dollars in Millions)	SIX MONTHS				
			Percent Change		
	2009	2008	Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$15,708	16,687	(5.9)%	(5.9)	-
Europe	7,643	8,855	(13.7)	0.8	(14.5)
Western Hemisphere excluding U.S.	2,277	2,525	(9.8)	8.2	(18.0)
Asia-Pacific, Africa	4,637	4,577	1.3	5.9	(4.6)
International	14,557	15,957	(8.8)	3.5	(12.3)
Worldwide	\$30,265	32,644	(7.3)%	(1.3)	(6.0)

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER		
	2009	2008	Percent
	Amount	Amount	Increase (Decrease)
	Percent to Sales	Percent to Sales	

Sales to customers	\$15,239	100.0	\$16,450	100.0	(7.4)
-----	-----	-----	-----	-----	-----
Cost of products sold	4,450	29.2	4,751	28.9	(6.3)
Selling, marketing and administrative expenses	4,797	31.5	5,507	33.5	(12.9)
Research & development expense	1,638	10.7	1,896	11.5	(13.6)
In-process research & development	-	-	40	0.2	
Interest (income) expense, net	85	0.6	16	0.1	
Other (income) expense, net	6	-	(135)	(0.8)	
-----	---	---	----	----	----
Earnings before provision for taxes on income	4,263	28.0	4,375	26.6	(2.6)
Provision for taxes on income	1,055	6.9	1,048	6.4	0.7
-----	-----	---	-----	---	---
Net earnings	\$3,208	21.1	\$3,327	20.2	(3.6)
-----	-----	----	-----	----	-----
Net earnings per share (Diluted)	\$1.15		\$1.17		(1.7)
Average shares outstanding (Diluted)	2,782.0		2,844.8		
Effective tax rate	24.7%		24.0%		

Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$4,263	28.0	\$4,415 (1)	26.8	(3.4)
Net earnings	\$3,208	21.1	\$3,367 (1)	20.5	(4.7)
Net earnings per share (Diluted)	\$1.15		\$1.18 (1)		(2.5)
Effective tax rate	24.7%		23.7%		

(1) The difference between as reported and as adjusted earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except
Per Share Figures)

SIX MONTHS

	2009		2008		Percent
	Amount	Percent to Sales	Amount	Percent to Sales	Increase (Decrease)
Sales to customers	\$30,265	100.0	\$32,644	100.0	(7.3)
Cost of products sold	8,701	28.7	9,365	28.7	(7.1)
Selling, marketing and administrative expenses	9,405	31.1	10,630	32.6	(11.5)
Research & development expense	3,156	10.4	3,608	11.1	(12.5)
In-process research & development	-	-	40	0.1	
Interest (income) expense, net	166	0.6	32	0.1	
Other (income) expense, net	(69)	(0.2)	(153)	(0.5)	
Earnings before provision for taxes on income	8,906	29.4	9,122	27.9	(2.4)
Provision for taxes on income	2,191	7.2	2,197	6.7	(0.3)
Net earnings	\$6,715	22.2	\$6,925	21.2	(3.0)
Net earnings per share (Diluted)	\$2.41		\$2.43		(0.8)
Average shares outstanding (Diluted)	2,785.5		2,856.1		
Effective tax rate	24.6%		24.1%		
Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$8,906	29.4	\$9,162 (1)	28.1	(2.8)
Net earnings	\$6,715	22.2	\$6,965 (1)	21.3	(3.6)
Net earnings per share (Diluted)	\$2.41		\$2.44 (1)		(1.2)
Effective tax rate	24.6%		24.0%		

(1) The difference between as reported and as adjusted earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER

	2009	2008	% Change		
			Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)					

SKIN CARE					

US	411	379	8.4%	8.4%	-
Intl	422	460	-8.3%	3.8%	-12.1%
WW	833	839	-0.7%	5.9%	-6.6%
BABY CARE					

US	104	111	-6.3%	-6.3%	-
Intl	404	461	-12.4%	-1.2%	-11.2%
WW	508	572	-11.2%	-2.2%	-9.0%
ORAL CARE					

US	174	185	-5.9%	-5.9%	-
Intl	212	223	-4.9%	9.5%	-14.4%
WW	386	408	-5.4%	2.4%	-7.8%
OTC/NUTRITIONALS					

US	679	679	-	-	-
Intl	631	726	-13.1%	0.6%	-13.7%
WW	1,310	1,405	-6.8%	0.3%	-7.1%
WOMEN'S HEALTH					

US	152	158	-3.8%	-3.8%	-
Intl	329	346	-4.9%	8.8%	-13.7%
WW	481	504	-4.6%	4.8%	-9.4%
WOUND CARE / OTHER					

US	188	182	3.3%	3.3%	-
Intl	148	126	17.5%	33.6%	-16.1%
WW	336	308	9.1%	15.7%	-6.6%
TOTAL CONSUMER					

US	1,708	1,694	0.8%	0.8%	-
Intl	2,146	2,342	-8.4%	4.7%	-13.1%
WW	3,854	4,036	-4.5%	3.1%	-7.6%

* See footnotes below

PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET

US	128	153	-16.3%	-16.3%	-
Intl	132	172	-23.3%	-10.6%	-12.7%
WW	260	325	-20.0%	-13.3%	-6.7%

CONCERTA

US	233	208	12.0%	12.0%	-
Intl	84	71	18.3%	38.0%	-19.7%
WW	317	279	13.6%	18.7%	-5.1%

DURAGESIC/FENTANYL TRANSDERMAL

US	50	70	-28.6%	-28.6%	-
Intl	168	202	-16.8%	-6.5%	-10.3%
WW	218	272	-19.9%	-12.3%	-7.6%

LEVAQUIN/FLOXIN

US	343	330	3.9%	3.9%	-
Intl	19	21	-9.5%	7.3%	-16.8%
WW	362	351	3.1%	4.1%	-1.0%

PROCRIT/EPREX

US	330	346	-4.6%	-4.6%	-
Intl	247	306	-19.3%	-7.6%	-11.7%
WW	577	652	-11.5%	-6.0%	-5.5%

RAZADYNE/REMINYL

US	16	42	-61.9%	-61.9%	-
Intl	91	110	-17.3%	-4.2%	-13.1%
WW	107	152	-29.6%	-20.1%	-9.5%

REMICADE

US	771	684	12.7%	12.7%	-
US Exports (4)	327	200	63.5%	63.5%	-
Intl	4	2	100.0%	96.2%	3.8%
WW	1,102	886	24.4%	24.4%	-

RISPERDAL/RISPERIDONE

US	70	492	-85.8%	-85.8%	-
Intl	169	220	-23.2%	-17.9%	-5.3%
WW	239	712	-66.4%	-64.8%	-1.6%

RISPERDAL CONSTA

US	131	120	9.2%	9.2%	-
Intl	217	223	-2.7%	13.7%	-16.4%
WW	348	343	1.5%	12.1%	-10.6%

TOPAMAX

US	75	548	-86.3%	-86.3%	-
Intl	107	129	-17.1%	-2.9%	-14.2%
WW	182	677	-73.1%	-70.4%	-2.7%

VELCADE

US	-	1	-100.0%	-100.0%	-
Intl	229	204	12.3%	26.9%	-14.6%
WW	229	205	11.7%	26.2%	-14.5%

OTHER

US	698	599	16.5%	16.5%	-
Intl	859	887	-3.2%	11.3%	-14.5%
WW	1,557	1,486	4.8%	13.5%	-8.7%

TOTAL PHARMACEUTICAL

US	3,172	3,793	-16.4%	-16.4%	-
Intl	2,326	2,547	-8.7%	3.3%	-12.0%
WW	5,498	6,340	-13.3%	-8.5%	-4.8%

MAJOR NEW PHARMACEUTICAL PRODUCTS (5)

PREZISTA

US	65	43	51.2%	51.2%	-
Intl	75	45	66.7%	90.0%	-23.3%
WW	140	88	59.1%	71.0%	-11.9%

INVEGA

US	67	62	8.1%	8.1%	-
Intl	32	14	128.6%	163.7%	-35.1%
WW	99	76	30.3%	36.6%	-6.3%

* See footnotes below

MEDICAL DEVICES AND DIAGNOSTICS (2)(3)

CORDIS (6)

US	252	328	-23.2%	-23.2%	-
Intl	422	485	-13.0%	-5.5%	-7.5%
WW	674	813	-17.1%	-12.6%	-4.5%

DEPUY

US	762	722	5.5%	5.5%	-
Intl	561	606	-7.4%	6.5%	-13.9%
WW	1,323	1,328	-0.4%	6.0%	-6.4%

DIABETES CARE

US	306	338	-9.5%	-9.5%	-
Intl	304	336	-9.5%	2.2%	-11.7%
WW	610	674	-9.5%	-3.7%	-5.8%

ETHICON

US	452	374	20.9%	20.9%	-
Intl	589	646	-8.8%	3.2%	-12.0%
WW	1,041	1,020	2.1%	9.7%	-7.6%

ETHICON ENDO-SURGERY

US	489	484	1.0%	1.0%	-
Intl	626	640	-2.2%	10.7%	-12.9%
WW	1,115	1,124	-0.8%	6.3%	-7.1%

ORTHO-CLINICAL DIAGNOSTICS

US	284	250	13.6%	13.6%	-
Intl	210	226	-7.1%	4.2%	-11.3%
WW	494	476	3.8%	9.2%	-5.4%

VISION CARE

US	231	227	1.8%	1.8%	-
Intl	399	412	-3.2%	2.0%	-5.2%
WW	630	639	-1.4%	1.9%	-3.3%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US	2,776	2,723	1.9%	1.9%	-
Intl	3,111	3,351	-7.2%	3.7%	-10.9%
WW	5,887	6,074	-3.1%	2.9%	-6.0%

- 1) Operational growth excludes the effect of currency
- 2) Select areas (unaudited)
- 3) Prior year amounts have been reclassified to conform with current presentation
- 4) For external purposes, reported as U.S. sales
- 5) Included in Other
- 6) Includes sales of Drug-Eluting Stents for Q2 2009 of \$69, \$165 and \$234 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2008 of \$167, \$227 and \$394 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of \$136, \$349 and \$485 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2008 of \$336, \$458 and \$794 million Domestic, International and Worldwide respectively

SIX MONTHS

			% Change		

2009	2008	Reported	Operational (1)	Currency	

CONSUMER SEGMENT (2)

SKIN CARE

US	834	761	9.6%	9.6%	-
Intl	841	918	-8.4%	4.6%	-13.0%
WW	1,675	1,679	-0.2%	6.9%	-7.1%

BABY CARE

US	206	226	-8.8%	-8.8%	-
----	-----	-----	-------	-------	---

Intl	791	879	-10.0%	1.5%	-11.5%
WW	997	1,105	-9.8%	-0.7%	-9.1%

ORAL CARE

US	362	384	-5.7%	-5.7%	-
Intl	389	410	-5.1%	10.4%	-15.5%
WW	751	794	-5.4%	2.6%	-8.0%

OTC/NUTRITIONALS

US	1,405	1,521	-7.6%	-7.6%	-
Intl	1,253	1,478	-15.2%	-0.9%	-14.3%
WW	2,658	2,999	-11.4%	-4.3%	-7.1%

WOMEN'S HEALTH

US	301	306	-1.6%	-1.6%	-
Intl	603	659	-8.5%	4.9%	-13.4%
WW	904	965	-6.3%	2.8%	-9.1%

WOUND CARE / OTHER

US	326	315	3.5%	3.5%	-
Intl	254	243	4.5%	19.4%	-14.9%
WW	580	558	3.9%	10.4%	-6.5%

TOTAL CONSUMER

US	3,434	3,513	-2.2%	-2.2%	-
Intl	4,131	4,587	-9.9%	3.6%	-13.5%
WW	7,565	8,100	-6.6%	1.0%	-7.6%

* See footnotes below

PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET

US	266	269	-1.1%	-1.1%	-
Intl	257	333	-22.8%	-9.5%	-13.3%
WW	523	602	-13.1%	-5.7%	-7.4%

CONCERTA

US	502	432	16.2%	16.2%	-
Intl	159	137	16.1%	37.6%	-21.5%
WW	661	569	16.2%	21.4%	-5.2%

DURAGESIC/FENTANYL TRANSDERMAL

US	125	145	-13.8%	-13.8%	-
Intl	324	360	-10.0%	1.8%	-11.8%
WW	449	505	-11.1%	-2.7%	-8.4%

LEVAQUIN/FLOXIN

US	751	804	-6.6%	-6.6%	-
Intl	36	43	-16.3%	2.0%	-18.3%
WW	787	847	-7.1%	-6.2%	-0.9%

PROCRIT/EXPRES

US	651	680	-4.3%	-4.3%	-
Intl	476	601	-20.8%	-8.7%	-12.1%
WW	1,127	1,281	-12.0%	-6.3%	-5.7%

RAZADYNE/REMINYL

US	29	92	-68.5%	-68.5%	-
Intl	179	209	-14.4%	0.2%	-14.6%
WW	208	301	-30.9%	-20.8%	-10.1%

REMICADE

US	1,508	1,360	10.9%	10.9%	-
US Exports (4)	613	520	17.9%	17.9%	-
Intl	9	4	125.0%	118.1%	6.9%
WW	2,130	1,884	13.1%	13.1%	-

RISPERDAL/RISPERIDONE

US	188	1,074	-82.5%	-82.5%	-
Intl	326	447	-27.1%	-21.3%	-5.8%
WW	514	1,521	-66.2%	-64.5%	-1.7%

RISPERDAL CONSTA

US	257	221	16.3%	16.3%	-
Intl	416	431	-3.5%	13.8%	-17.3%
WW	673	652	3.2%	14.6%	-11.4%

TOPAMAX

US	570	1,068	-46.6%	-46.6%	-
Intl	214	255	-16.1%	-1.4%	-14.7%
WW	784	1,323	-40.7%	-37.9%	-2.8%

VELCADE

US	-	3	-100.0%	-100.0%	-
Intl	421	386	9.1%	24.5%	-15.4%
WW	421	389	8.2%	23.5%	-15.3%

OTHER

US	1,386	1,195	16.0%	16.0%	-
Intl	1,615	1,700	-5.0%	10.4%	-15.4%
WW	3,001	2,895	3.7%	12.7%	-9.0%

TOTAL PHARMACEUTICAL

US	6,846	7,863	-12.9%	-12.9%	-
Intl	4,432	4,906	-9.7%	3.1%	-12.8%
WW	11,278	12,769	-11.7%	-6.8%	-4.9%

MAJOR NEW PHARMACEUTICAL PRODUCTS (5)

PREZISTA

US	137	75	82.7%	82.7%	-
Intl	125	87	43.7%	66.5%	-22.8%
WW	262	162	61.7%	73.9%	-12.2%

INVEGA

US	133	119	11.8%	11.8%	-
Intl	57	23	147.8%	186.4%	-38.6%
WW	190	142	33.8%	39.9%	-6.1%

* See footnotes below

MEDICAL DEVICES AND DIAGNOSTICS (2)(3)

CORDIS (6)

US	498	670	-25.7%	-25.7%	-
Intl	844	944	-10.6%	-3.6%	-7.0%
WW	1,342	1,614	-16.9%	-12.8%	-4.1%

DEPUY

US	1,528	1,431	6.8%	6.8%	-
Intl	1,087	1,184	-8.2%	6.5%	-14.7%
WW	2,615	2,615	-	6.6%	-6.6%

DIABETES CARE

US	576	641	-10.1%	-10.1%	-
Intl	575	648	-11.3%	0.5%	-11.8%
WW	1,151	1,289	-10.7%	-4.8%	-5.9%

ETHICON

US	857	715	19.9%	19.9%	-
Intl	1,137	1,250	-9.0%	3.5%	-12.5%
WW	1,994	1,965	1.5%	9.4%	-7.9%

ETHICON ENDO-SURGERY

US	943	913	3.3%	3.3%	-
Intl	1,187	1,214	-2.2%	11.1%	-13.3%
WW	2,130	2,127	0.1%	7.3%	-7.2%

ORTHO-CLINICAL DIAGNOSTICS

US	561	488	15.0%	15.0%	-
Intl	400	431	-7.2%	3.8%	-11.0%
WW	961	919	4.6%	9.7%	-5.1%

VISION CARE

US	465	453	2.6%	2.6%	-
Intl	764	793	-3.7%	0.5%	-4.2%
WW	1,229	1,246	-1.4%	1.3%	-2.7%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US	5,428	5,311	2.2%	2.2%	-
Intl	5,994	6,464	-7.3%	3.6%	-10.9%

WW

11,422 11,775 -3.0% 3.0% -6.0%

- 1) Operational growth excludes the effect of currency
- 2) Select areas (unaudited)
- 3) Prior year amounts have been reclassified to conform with current presentation
- 4) For external purposes, reported as U.S. sales
- 5) Included in Other
- 6) Includes sales of Drug-Eluting Stents for Q2 2009 of \$69, \$165 and \$234 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q2 2008 of \$167, \$227 and \$394 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2009 of \$136, \$349 and \$485 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for June YTD 2008 of \$336, \$458 and \$794 million Domestic, International and Worldwide respectively

SOURCE Johnson & Johnson

<http://www.jnj.com>

Copyright © 2009 PR Newswire. All rights reserved